The Pharma Data

JANUARY 17, 2021

Ophthalmologists are physicians who have completed four years of medical school and four years of residency training. They aren’t doctors, according to the American Association of Certified Orthoptists. Treatments they help administer include patching therapy, prisms and convergence exercises. © 2021 HealthDay.

Medical Schools 52

Medical Schools Doctors Treatment Disease 52

Drug Target Review

MARCH 15, 2024

He has a post-doctorate in virology, viral pathogenesis, viral vector development, and vaccines evaluation from Harvard Medical School, and a PhD in virology/molecular biology. Cell Gene Therapy Insights 2017; 3(2), 131-158, 10.18609/cgti.2017.014. Biotechnol Prog. 2017 Nov;33(6):1468-1475. doi: 10.1002/btpr.2548.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

Broad Institute

OCTOBER 23, 2024

The work highlights the importance of examining the often-ignored noncoding parts of the genome when diagnosing rare genetic disorders, and also points to possible future genetic therapies that fine-tune CHASERR abundance as a means to treat CHASERR - and CHD2 -related disorders.

DNA 128

DNA RNA Disease Hospitals 128

Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

Broad Institute

MAY 2, 2024

In undergrad, I thought about going to medical school, but I didn’t want to work in a hospital. If you find a novel mutation that you target with a drug in a specific cancer type, you can help people in a really impactful way even though you’re not the doctor treating their disease. You think, “I’ve created something new.”

Science 124

Science Medical Schools Disease Hospitals 124

The Pharma Data

JANUARY 27, 2021

Yet insurance does not cover the therapy for stroke patients. That’s partly because after a stroke, the emphasis is often on rehab for any disabilities a patient might have, said Elizabeth Regan, a clinical assistant professor of physical therapy at the University of South Carolina, in Columbia. 27, 2021, online.

Medical Schools 52

Medical Schools Therapies Hospitals Doctors 52

Broad Institute

JULY 26, 2022

By Stephanie Dutchen, Harvard Medical School Office of Communications and External Relations July 26, 2022 Credit: Susanna Hamilton, Broad Communications From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease. Study after study had suggested that A.

Research 52

Research Immune Response Medical Schools Disease 52

NIH Director's Blog: Drug Development

APRIL 2, 2020

This is of particular concern to doctors whose patients are already taking the medications to control hypertension. Since the COVID-19 outbreak, many people have wondered whether taking ACE inhibitors would be helpful or detrimental against coronavirus infection. The team, led by Scott D.

Drug Development 52

Drug Development Drugs Science Medical Schools 52

Broad Institute

JUNE 21, 2023

Typically, studying drug therapies is an expensive and time-consuming undertaking. By makenziekohler June 23, 2023 Related Claussnitzer Lab first paragraph The field of microscopy has grown immensely over the last fifty years in its ability to extract both quantitative and qualitative data from microscopic images.

Small Molecule 52

Small Molecule Cell Based Assays Medical Schools Disease 52

The Pharma Data

DECEMBER 3, 2020

An initial analysis of data from 17/22 patients who completed one of these assessments showed substantially decreased neurocognitive abilities compared to children of the same age level despite the use of multiple anti-epileptic therapies. No investigational medications or other treatments will be provided. Lori Isom, Ph.D.,

Clinical Trials 52

Clinical Trials Protein Expression Pharmacokinetics Trials 52

Broad Institute

NOVEMBER 6, 2024

We are incredibly grateful to each and every patient who partnered with us, all those involved in their clinical care, and the exceptional team in our lab who made this research possible.” “This work provides a biological foundation for testing more targeted therapies for myocarditis due to an immune checkpoint inhibitor.

Immune Response 125

Immune Response Medical Schools Clinical Trials Treatment 125

Drug Target Review

MARCH 20, 2025

The landscape of anticoagulation therapy could be on the brink of a major transformation. GI bleeding can lead to patients temporarily or permanently discontinuing their anticoagulation therapy, significantly increasing their stroke risk. “When someone has a GI bleed, they often stop taking their anticoagulant.

Therapies 52

Therapies Trials Clinical Development FDA 52

Broad Institute

NOVEMBER 6, 2024

Earlier this year, the researchers shared their first translational results, describing the immune cell response underlying colon inflammation in patients undergoing ICI therapy. These are home-run, breakthrough therapies, and quite an amazing success story. How big of a problem are these complications from cancer immunotherapy?

Research 131

Research Immune Response Hospitals Therapies 131

keypoint

JANUARY 8, 2025

Dr. Cheruiyot is a post-doctoral fellow at the Joslin Diabetes Center, Harvard Medical School (HMS) I n the lab of Dr. Jean Schaffer, s he studies molecular mechanisms underlying protein synthesis in pancreatic beta cells, and alterations of such mechanisms in diabetes.

Medical Schools 59

Medical Schools RNA Laboratories Doctors 59

Elrig

MARCH 10, 2025

The free-to-attend event will bring together scientists, researchers and entrepreneurs from across the drug discovery community working on proteins, RNA, cell and gene therapies, PROTACs, as well as the application of big data to support target identification, biomarkers and the development of big molecules.

Research 52

Research Laboratories Medical Schools Engineering 52